AlphAIAlphAI — Financial news for AI agents
theglobeandmail.comOCT 62 min read$ABBV

AbbVie's Epcoritamab Combo Shows PFS Benefit in Frontline DLBCL

AbbVie (ABBV) and Genmab (GMAB) reported positive phase III trial results for epcoritamab combined with R-CHOP in frontline DLBCL, showing a 51% reduction in disease progression or death. The study met its primary endpoint, and the combo was well-tolerated. Both companies plan regulatory discussions. AbbVie's shares are up 19.1% YTD. Epcoritamab is approved as a monotherapy in several regions.

Original reporting
theglobeandmail.com
Published Oct 6, 2026, 4:41 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 6, 2026, 5:14 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AbbVie's Epcoritamab Combo Shows PFS Benefit in Frontline DLBCL — source image
Source · theglobeandmail.com
Decision brief

The 30-second read

$ABBVBullishHigh
01

Why it matters

The data positions AbbVie as a leader in bispecific oncology therapies and may accelerate FDA discussions, influencing investor sentiment positively.

02

Market read

First‑time disclosure of pivotal trial results likely to move AbbVie's share price and affect the broader oncology sector.

03

What to watch

Potential competition from other bispecifics and the need for commercial rollout capabilities.

Relevance 9/10Novelty 9/10Timing: same-day release

Background

AbbVie and partner Genmab disclosed interim Phase III results for epcoritamab combined with R-CHOP in frontline diffuse large B‑cell lymphoma, showing a statistically significant PFS improvement.

Company-level read

Ticker impact

$ABBVBullishHigh confidence
Context

AbbVie announced positive Phase III EPCORE DLBCL-2 trial data showing a 51% reduction in risk of progression or death with epcoritamab + R-CHOP.

Expected impact

upward pressure as the market prices in potential future sales and upside from the new indication.

Evidence & confidence

Phase III data is a material, first‑time disclosure; the magnitude of PFS benefit is clinically significant and could drive near‑term price appreciation.

Market effects

Sector

Strengthens the oncology pipeline outlook for large‑cap pharma and may raise expectations for other bispecific programs.

Regional

Positive for US biotech sector; limited immediate effect on European markets.

Global

Adds to global interest in novel immunotherapies and could influence peer valuations.

Counterpoint

What could challenge this read

If regulatory hurdles delay approval, the stock could face disappointment despite strong data.

Key entities

  • company
    AbbVie

    US‑listed pharmaceutical company (ticker ABBV) developing epcoritamab.

  • company
    Genmab

    Denmark‑based biotech partner co‑developing epcoritamab.

Read at source← All news

Also covered by

4 outlets

Related articles

OCT 6
$ABBVMed

AbbVie Stocks Edge Higher as Lymphoma Trial Cuts Progression Risk 51%

AbbVie (ABBV) shares rose 0.3% to $266.63 on Oct. 6 after a late-stage trial showed its blood-cancer treatment, epcoritamab plus R-CHOP, reduced the risk of disease progression or death by 51% compared to R-CHOP alone in diffuse large B-cell lymphoma. The trial's hazard ratio was 0.49, with a p-value below 0.0001, and safety was consistent with known profiles.

finance.yahoo.com2 min
OCT 6
$ABBVHighAI 9/10

Dual-acting drug from AbbVie, Genmab scores in frontline lymphoma trial

Genmab and AbbVie's Epkinly, combined with chemotherapy, reduced disease progression or death risk by 51% in a Phase 3 lymphoma trial. The results exceeded expectations and could boost Epkinly's sales. Genmab reported $312M in Epkinly sales in H1 2024, and its shares rose 14% on the news. Epkinly may become the first drug of its kind approved for first-line DLBCL.

finance.yahoo.com2 min
OCT 6
$ABBVMed

AbbVie and Genmab Report 51% Reduction in Progression With Epcoritamab Plus R-CHOP in Diffuse Large B-cell Lymphoma

AbbVie and Genmab reported Phase 3 trial results showing a 51% reduction in disease progression or death for epcoritamab plus R-CHOP in diffuse large B-cell lymphoma (DLBCL) patients with IPI scores of 2-5. The combination therapy met its primary endpoint, improving progression-free survival. The companies plan to discuss the findings with regulators. Epcoritamab is an investigational bispecific antibody.

oncodaily.com2 min
OCT 6
$ABBVHighAI 9/10

AbbVie, Genmab’s Epkinly sets ‘new standard of care’ in first-line lymphoma in Phase 3

AbbVie and Genmab's Epkinly reduced disease progression or death risk by 51% in a Phase 3 trial for frontline DLBCL treatment, exceeding expectations. The study enrolled 900 patients and showed significant improvement over R-CHOP alone. Genmab's shares rose 11% following the data release. Epkinly is already approved for later-stage treatment and could compete with Roche's Polivy and Incyte's Monjuvi if approved for first-line use.

biospace.com2 min